<DOC>
	<DOCNO>NCT01186887</DOCNO>
	<brief_summary>The aim study directly compare clinical outcome celecoxib placebo group follow anterior cruciate ligament ( ACL ) reconstruction . The study short long term goal . Validated outcome measure aim quantify pain control 2 week surgery , well knee function 2 year follow-up . Groups compare use pain control scale , functional knee outcome score . The first null hypothesis test study celecoxib group experience equal pain control compare placebo group . The second null hypothesis knee function difference find celecoxib placebo group .</brief_summary>
	<brief_title>A Trial Assessing Outcome Celecoxib Administration Versus Placebo Following Anterior Cruciate Ligament ( ACL ) Reconstruction</brief_title>
	<detailed_description />
	<mesh_term>Polystyrene sulfonic acid</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>Any patient 18 year undergoing primary anterior cruciate ligament reconstruction hamstring graft consider study . Patients exclude bilateral ACL injury , require revision ACL reconstruction , require meniscus repair , multiple ligament injury , gross osteoarthritis , significant clinical malalignment attend appropriate followup . Other exclusion criterion include use regional block surgery , diagnosis esophageal , gastric , duodenal ulceration , hepatic disease , renal disease , hypertension , hypersensitivity Celecoxib , know allergictype reaction sulfonamide , know allergy ASA NSAIDS , inflammatory bowel disease hyperkalemia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>primary ACL reconstruction hamstring graft</keyword>
</DOC>